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Mechanical circulatory assist devices have been used in
clinical practice as a bridge to transplantation since the
late 1960s. In 1982, the first totally artificial heart desig-
nated as permanent therapy was implanted, but relatively
few totally artificial hearts are implanted today. In the
last several years, there has been a shift toward the use of
left ventricular assist devices as a bridge to cardiac trans-
plantation. Likewise, there is increasing interest in the
use of ventricular assist devices as a bridge to recovery for
patients with myocarditis, dilated cardiomyopathy, and
following myocardial infarction or cardiotomy. This re-
view presents basic information on the present use of these
devices as they relate to transplantation and recovery,
and as permanent therapy. Individual devices will briefly
be described, as will indications for, and timing of, im-
plantation. Other related issues, such as right heart failure,
pulmonary hypertension, arrhythmias, anticoagulation,
and infections, will be addressed. In closing, the future of
mechanical circulatory devices will be discussed.
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History
The concept of replacing the failing human heart
with a mechanical assist device dates back at least
several hundred years. Early prototypes of ventricu-
lar assist devices began to emerge in the late 1800s
and early 1900s. In 1928, H.H. Dale and E.H.J.
Schuster developed the first diaphragm perfusion
pump1 and in 1934 Michael DeBakey developed
the roller pump.2 In 1935, a combined pump oxy-
genator was designed by Charles Lindbergh and
Alexis Carrel in response to the illness of Lind-
bergh’s sister-in-law, who suffered from valvular
heart disease.3
The modern era of cardiac surgery began in
1952 with the first clinical use of a form of total me-
chanical cardiac assist, the heart-lung machine, de-
signed by John Gibbon.4 Shortly thereafter, a totally
artificial heart (TAH) developed by Drs. Willem
Kolff and Tetsuzo Akutsu sustained a dog for 90
minutes.5 In 1967, Dr. Adrian Kantrowitz described
the first use of an intra-aortic balloon pump,6 which
to this day is the most widely used form of mechani-
cal cardiac assist.
Denton Cooley performed the first human im-
plant of a totally artificial heart in 1969.7 The de-
vice, designed by Domingo Liotta, successfully
supported a patient for 64 hours until a donor
heart was located. Totally artificial hearts have been
used since that time as bridges to transplantation.
To date, the most well publicized use of an artificial
heart occurred in 1982 when Dr. William DeVries
implanted a Jarvik-7 TAH into Dr. Barney Clark, a
61-year-old dentist who suffered from end stage
cardiomyopathy.8 The patient’s age and degree of
pulmonary hypertension were contraindications to
cardiac transplantation, and the device was im-
planted as a means of permanent therapy. Dr.
Clark survived for 112 days before ultimately suc-
cumbing to sepsis and multisystem organ failure.
Several more permanent implantations were per-
formed, with disappointing results, and the device
was relegated to use as a bridge to transplantation.
By 1985, multicenter trials to evaluate the use of
left ventricular assist devices (LVAD) as a bridge to
transplantation demonstrated promising results,
and by 1994 the FDA had approved the use of a
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LVAD for this indication.9 Although TAHs are still
used clinically, LVADs, or more accurately, left ven-
tricular assist systems (LVAS), are now the im-
plantable devices most commonly used. With the
initiation of the Randomized Evaluation of Mechan-
ical Assistance for the Treatment of Congestive
Heart Failure (REMATCH) trial,10 a comparison of
the use of the TCI HeartMate LVAS vs. the best
medical therapy for patients with severe heart fail-
ure, we once again turn toward the use of these de-
vices as permanent, or destination, therapy.
Indications and Timing
In broad terms, indications for use of an assist de-
vice include failure to wean from cardiopulmonary
bypass, inability to safely bridge a patient to trans-
plant using standard medical and surgical thera-
pies, cardiogenic shock in both transplant and
non-transplant candidates, and life-threatening ar-
rhythmias not amenable to medical or surgical ther-
apy. The threshold for placing an assist device is
related to the comfort level and experience of the
cardiovascular surgeon and cardiologist, the types
of assist devices at their disposal, and the local stan-
dard of care. Specific guidelines are listed in the
Table. At our institution, criteria for placement of
an assist device are not absolute, and the choice to
proceed is individualized to the patient. For exam-
ple, a patient with a cardiac index of 1.8 L/min/m2
who has relatively good blood pressure, has no end
organ dysfunction, and is reasonably well perfused
might not benefit from implantation of a LVAD. In
comparison, a patient with a cardiac index of 1.8
L/min/m2, whose blood pressure is only 75/62 and
serum sodium is 125, is likely to benefit from LVAD
implantation.
While many patients with end stage heart disease
have evidence of ongoing end organ dysfunction,
implantation of a ventricular assist device is not con-
traindicated, provided that the dysfunction is not se-
vere, or that it is believed to be reversible. For
patients in whom the device is used as a bridge to
transplantation, exclusion criteria are similar to the
criteria used for transplant candidacy, with a few no-
table additions. For most devices, there is a patient
size limit. For example, it is difficult to implant a
Novacor® or HeartMate® if the body surface area of
the patient is less than 1.5 m2, or a CardioWest®
TAH if the body surface area is <1.7 m2. These gen-
eral guidelines are somewhat dependent on the
body habitus of the patient as well.
Severe coagulopathy poses a substantial surgical
challenge, and is a strong relative if not absolute
contraindication to implantation of most forms of
assist devices. Likewise, severe hepatic dysfunction
is felt to be a contraindication to LVAD implanta-
tion, largely because of the resultant uncontrollable
coagulopathy. In one series, preoperative hepatic
dysfunction was the most consistent predictor of
poor outcome.11 We have used percutaneously
placed extracorporeal membrane oxygenation
(ECMO), more accurately known as extracorporeal
life support (ECLS), to effect rapid and complete
venous unloading, improve systemic perfusion, and
optimize oxygen delivery, with the result of im-
provement in congestive hepatopathy and coagu-
lopathy. With this strategy, the rate of LVAD
survival after initial ECLS support of very high risk
patients is not significantly different from the sur-
vival rate after LVAD placement alone in lower risk
patients.12 This strategy is also cost-effective be-
cause LVAD implantation, an expensive form of
support, is not performed in those who do not sur-
vive the initial ECLS, which is a substantially less
expensive option.
Profound or even complete renal dysfunction, al-
though a risk factor for poor outcome,13 can be
managed with traditional renal replacement therapy
(continuous veno-venous hemofiltration [CVVH],
continuous veno-venous hemofiltration with he-
TABLE. INDICATIONS FOR THE INITIATION OF
A MECHANICAL CIRCULATORY ASSIST DEVICE
AS A BRIDGE TO TRANSPLANT
MUST MEET CRITERIA FOR TRANSPLANTATION
• Hemodynamic criteria:
• Cardiac index <2.0 despite optimal inotropic therapy
• Inability to maintain adequate SBP
• PCWP >20
• Reversible neurologic dysfunction secondary to 
low flow
• Reversible renal dysfunction secondary to low flow
• Inability to maintain salt/water homeostasis despite
diuretics and inotropic therapy
• Inability to wean from ventilator secondary to 
persistent pulmonary edema
• Inability to wean from IABP
• Malignant, uncontrollable arrhythmias
• Life-threatening coronary anatomy not amenable 
to percutaneous or surgical correction
OTHER INDICATIONS
• Failure to wean from CPB—postcardiotomy 
syndrome
• As a bridge to ventricular recovery 
(example: acute myocarditis)
• REMATCH candidate10
PCWP=pulmonary capillary wedge pressure;
SBP=systolic blood pressure; IABP=intra-aortic 
balloon pump; CPB=cardiopulmonary bypass.
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modialysis [CVVH-D], or hemodialysis). In the set-
ting of reversible renal dysfunction (such as acute
tubular necrosis), substantial renal function usually
returns within days to weeks after adequate perfu-
sion is established by an assist device.
Appropriate timing for placement of a LVAD
must be individualized to the patient. The window
of opportunity is frequently narrow. The rule is to
avoid implantation of a LVAD if it appears that
standard medical therapy (for example, inotropes,
diuretics, or implantable defibrillators) can safely
bridge a patient to transplant. This assumes that
during the waiting time for a donor organ, the pa-
tient can be active and mobile enough that ade-
quate nutritional status, muscle mass, and strength
are maintained, as severely debilitated patients
have a much higher post-transplant mortality. If a
reasonably appropriate physiology cannot be
maintained, implantation of a LVAD is
warranted.14 Implantation of a LVAD results in
normalization of end organ function, which facili-
tates recovery to a healthier state than that prior
to transplantation. If implantation is delayed for
too long, profound end organ dysfunction can
render a patient too ill to survive the implantation
procedure. A risk factor selection scale based on
easy-to-obtain clinical and laboratory data has
been developed to help identify patients at high
risk for LVAD postoperative death.15 In cases
where risk is determined to be prohibitively high
secondary to physiologic derangements, utilizing
other means of ventricular support can help
bridge the patient to a physiologic state compati-
ble with LVAD implant survival.12 Intra-aortic bal-
loon counterpulsation, ECLS, and some of the
extracorporeal devices can be extremely helpful in
these situations.
We would like to think that economics should
not play a role in deciding the most appropriate
therapy for a patient. However, with the high cost
of chronic intensive care, we are forced to consider
the economics carefully. Despite the fact that an im-
plantable LVAS is very costly, most of the cost is up
front. Many of these patients can ultimately be dis-
charged from the hospital to live at home, with
minimal further cost.16,17 On the other hand, a sin-
gle prolonged hospital admission, multiple hospital
admissions, or home inotropic support, might in
fact be even more costly.18 Consider the patient
who is likely to be chronically hospitalized, but is
unlikely to be transplanted within a short period of
time because of body size, blood type, or panel re-
active antibody status. In this patient, utilization of
a LVAS would be a clinically and economically
sound decision.
Devices Most Commonly 
Used in the U.S. 
There are many forms of mechanical circulatory as-
sist devices. A few are available only at tertiary or
transplant centers, but many are available at hospi-
tals that have either a catheterization laboratory or
cardiac surgery capability. Approximately 35% of
our LVAS patients are placed on some form of ven-
tricular or circulatory support prior to transfer to
our institution. Our recent success with LVADs and
transplantation is a tribute to other physicians’ abil-
ity to identify, triage, and appropriately manage pa-
tients with profound cardiac disease. With this in
mind, we feel that it is appropriate to review all
forms of mechanical circulatory assist devices so
that this practice might continue. 
Intra-Aortic Balloon Counterpulsation. This
mode of ventricular assist is the most widely used
form of mechanical ventricular support. Any form
of left ventricular systolic dysfunction can be sup-
ported by the use of an intra-aortic balloon pump
(IABP). An IABP can be used as a short-term bridge
to recovery or transplant. One of the advantages of
an IABP is that the device is reasonably portable,
allowing hospital-to-hospital transfer without inter-
ruption of therapy. The major limitation is the rela-
tively limited degree of support achieved with an
IABP as compared to an implantable LVAD. Under
optimal conditions, an IABP can increase cardiac
index by only 15%–30%.
The IABP is usually emplaced percutaneously
(occasionally by cut-down) via the femoral artery.
Insertion can be performed in a cardiac catheteriza-
tion laboratory, an operating room, and by skilled
hands, at the bedside. The mechanism of action is
dual. During diastole, balloon inflation augments
aortic arterial pressure, with a resulting improve-
ment in coronary perfusion. During systole, balloon
deflation causes significant afterload reduction. The
end result is improved myocardial and systemic
oxygen delivery, decreased myocardial workload,
and improved mean arterial pressure.
Contraindications to use of an IABP include se-
vere aorto-ilio-femoral disease, aortic insufficiency,
and aortic dissection. Risks include infection,
bleeding, vascular trauma, embolization with loss of
limb or end organ ischemia, and other difficulties
caused by the immobilization required during sup-
port. The risk increases in proportion to duration
of support, and because of this, an IABP is not the
assist device of choice for long-term support. Sys-
temic anticoagulation with heparin is generally re-
quired for prolonged use.
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Extracorporeal Life Support (ECLS/ECMO).
These devices usually employ either roller pumps or
centrifugal pumps in combination with a membrane
oxygenator. The simplest form of this type of sup-
port is the heart-lung or cardiopulmonary bypass
(CPB) machine, which can be used as a short-term
bridge to a more permanent form of support. Long-
term types of ECLS have largely been used in
neonates and adults with acute respiratory distress
syndrome. Although a few adult patients have been
bridged to transplant with ECLS, the complications
that occur with relatively brief support preclude its
use for long-term ventricular support. It has been
used as an effective short-term bridge to cardiac re-
covery. At other institutions13 as well as our own,12
the indications for ECLS has been extended to car-
diac patients with profound end organ dysfunction
as a bridge to LVAD implantation.
Advantages of this type of system include percu-
taneous cannulation, full oxygenation as well as
perfusion, and weaning capabilities. It can com-
pletely unload the venous system, allowing for reso-
lution of congestive hepatopathy and nephropathy.
Various forms of dialysis can be added in-line. Atri-
al septostomy should be performed by an experi-
enced catheterization laboratory during ECLS
support in the case of incomplete left atrial/ventric-
ular unloading, in order to prevent pulmonary he-
morrhage.19 At our institution, ECLS has been used
successfully to provide temporary right ventricular
assist (RVA[D]) after implantation of a LVAD, and is
our RVAD of choice. We have used ECLS to treat
severe pulmonary capillary leak syndrome sec-
ondary to a protamine reaction during LVAD im-
plantation, and also in a similar situation (related to
OKT3-induced cytokine release syndrome) after
cardiac transplantation. Biventricular support can
be achieved through venoarterial cannulation. It
can be quickly implemented in cardiac arrest situa-
tions, particularly in the case of severe, uncontrol-
lable ventricular arrhythmias.
An additional advantage to ECLS is that it is
portable (our ECLS team routinely travels to outly-
ing hospitals where ECLS is initiated, and the patient
is transported to our institution by ground or air).
Many cardiac catheterization laboratories have per-
cutaneous cardiopulmonary bypass support (PCPS
or CPS) capability, which is essentially a scaled down
form of ECLS used for short-term support during
high risk interventions. PCPS can be utilized to
maintain a patient until arrival of the ECLS team.
Switching over to ECLS from PCPS requires only up-
sizing of the previously placed percutaneous lines.
Disadvantages and risks include the need for full
anticoagulation with heparin, patient immobility,
infection, hemolysis, and the potential for em-
bolization. Although ECLS is portable in our state,
many regions do not have access to ECLS.
Centrifugal Pumps (Sarns Delphin® and Bio-
medicus® pumps). These devices (CPs) are com-
monly used as the pump in cardiopulmonary
bypass circuits. They are non-pulsatile devices that
use centrifugal force to draw in and propel blood
via inflow and outflow cannulae that enter the body
through subcostal incisions. CPs can be used for
uni- or biventricular support, can be implanted at
any cardiac surgery center, are inexpensive, and
are portable for patient transfer. They are best used
for short periods of support (hours to days), hemol-
ysis being the rate-limiting factor. These devices are
frequently used in combination with intra-aortic
counterpulsation. Systemic heparinization is re-
quired. Bedside operation requires the presence of
a perfusionist.
ABIOMED BVS 5000® (ABIOMED, Inc., 
Danvers, MA). This system is specifically designed
as a form of ventricular support. It consists of an
external pneumatic drive console, single-use extra-
corporeal blood pumps, and cannulae that enter
the body through subcostal incisions. It can be con-
figured as a RVAD, a LVAD, or a BiVAD, depend-
ing on the needs of the patient. The atria are the
usual sites of inflow cannulation; however, left ven-
tricular apical and right ventricular free wall cannu-
lation are occasionally used. The great vessels are
the usual sites for outflow cannulation, although
transpulmonic valve cannulation for pulmonary
outflow is occasionally used. Some surgeons have
used a left mini-thoracotomy approach for less in-
vasive cannulation. The design of the blood pump
is unique. Blood flows via gravity drainage into the
device inflow bladder, which functions as the atria
of the device. Blood then passively flows across a
trileaflet polyurethane inflow valve into the outflow
bladder, which acts as the ventricle of the device.
When this bladder fills, the console sends a pulse of
compressed air into the gap between the surround-
ing plastic casing and the bladder. The resulting in-
crease in pressure, which is transmitted to the
blood column within the bladder, causes device
“ventricular systole.” Pulsatile blood flow is deliv-
ered to the patient through a second trileaflet valve
and outflow cannula, with flows of up to 6 L/min.
The console is simple to use, and relatively little
monitoring is needed. It is FDA-approved as a
bridge to any form of myocardial recovery, but is
frequently used as a short- to medium-term bridge
to a long-term ventricular assist device or trans-
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plant. It can be implanted at any center that has
cardiac surgery capability, and it is portable for
center-to-center patient transfer. Systemic anticoag-
ulation is required during support. In contrast to
CPs, there is no need for a perfusionist; the device
can be maintained by trained nursing staff. To date,
the smallest patient successfully supported with this
device is a 7 year-old boy with a body surface area
of 0.85m2. Although the system is bulky, patient
ambulation is possible. 
Thoratec® VAD System (Thoratec Laborato-
ries Corporation, Pleasanton, CA). This device
was initially designed by Dr. William Pierce and
James Donachy at Pennsylvania State University.
The pneumatically driven, pulsatile blood pump is
designed for use as a RVAD, LVAD, or BiVAD, de-
pending on the needs of the patient. The blood
pump consists of a smooth, seamless polyurethane
pumping chamber enclosed in a rigid case. Two
mechanical valves maintain unidirectional flow.
The stroke volume is 65 ml, with flow outputs that
range from 1.3–7.2 L/min. The cannulation tech-
nique is variable, with inflow to the device through
cannulation of the ventricles or atria and outflow
from the device through cannulation of the great
vessels. The blood pump(s) is paracorporeal, mak-
ing it the most versatile system on the market. Be-
cause the device itself is outside the body, it can be
used to support smaller patients, the smallest to
date being a 17-kg patient with a BSA of 0.7 m2.
The drive console provides alternating pulses of
vacuum and pressure to the device. It can be set in
one of three different modes of operation, one of
which allows for changes in device output, depend-
ing on the device inflow (venous return) of the pa-
tient. Although the console is quite large, a much
smaller portable driver (the TLC-IITM) is current-
ly in use in Europe and is under investigation in
the U.S. The Thoratec VAD is the only device ap-
proved by the FDA for both bridge to transplant
and postcardiotomy support. For the combined in-
dications, this device has been used to support 912
patients to date. The longest duration of support
with the Thoratec device is 515 days; the patient,
who received univentricular support, was success-
fully transplanted. 
Use of this device requires systemic anticoagula-
tion. Heparin is administered after surgical bleeding
is controlled, and is generally changed to warfarin
during long-term use. Use of this device is primarily
restricted to tertiary/transplant centers, as it requires
expertise and resources not available in community
hospitals. Patients can be discharged from the hos-
pital while being supported by this device.
HeartMate® IP-LVAS and VE-LVAS (Thermo
Cardiosystems Inc., Woburn, MA). There are
actually two different HeartMate LVAD systems.
Both consist of an implantable blood pump, which
comprises a titanium alloy housing that contains a
pusher plate behind a flexible polyurethane di-
aphragm. The inflow cannula is attached to the left
ventricular apex, and the outflow cannula is anasto-
mosed to the ascending aorta. Porcine valves within
each cannula maintain unidirectional blood flow.
The device is implanted in the left upper quadrant,
either within the abdominal cavity or in a preperi-
toneal pocket, depending on the preference and ex-
perience of the surgeon.
One of the unique features of this device is that
all blood-contacting surfaces (except the cannulae)
are textured to promote the formation of a tightly
adherent biologic pseudo-neointima, which allows
blood to contact only a biologic surface. The titani-
um half of the interior of the device is lined with sin-
tered titanium microspheres. The polyurethane half
of the interior is similarly irregular. As a result, this
device boasts an extraordinarily low thromboembol-
ic rate of 2%–4%.20,21 Systemic anticoagulation is not
required, although daily aspirin is recommended. 
The two devices differ in the way the pusher
plate is activated. For the pneumatic model (IP-
1000 LVAS), an external console pneumatically ac-
tivates the pusher plate through a driveline that
exits the body through a stab wound in the abdomi-
nal wall. In the Vented Electric model (VE LVAS),
an electric motor is housed behind the pusher
plate. The motor is coupled to the external con-
troller and console through a driveline that exits
the body through a stab wound in the abdominal
wall. Because this device requires venting of air in
the motor section of the device, the driveline also
serves as a vent. Should a problem develop with the
motor or other electric components of the device,
the vent can be attached to a pneumatic console,
and the device becomes a functional IP-LVAS. 
Both devices can be operated in two different
modes: fixed rate and automatic. In automatic
mode, the cardiac output is determined by the de-
vice inflow (venous return) of the patient, allowing
for increased flow during exercise. The IP-1000
LVAS can support flows of up to 11.7 L/min, and the
VE LVAS up to 10 L/min. The external console of
the IP-1000 LVAS is bulky, and despite the fact that
these patients are quite mobile, they usually remain
hospitalized because of the size of the external con-
sole. A smaller portable console, the HeartPak®, is
currently undergoing clinical trials. The VE LVAS
console is smaller than the pneumatic console, and
this device can be operated with two small, wearable
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battery packs, which allow for untethered mobility
for 8 hours per battery pair. Many of these patients
can be discharged to home with relatively normal
mobility. They can participate in activities such as
shopping, golf, and walking. Many can return to
work. To date, 2095 HeartMate devices have been
implanted worldwide. The longest duration of sup-
port thus far is 873 days.
Use of this device is limited to patients with a
BSA of 1.5 m2 or greater. Because it is a pure
LVAD, it provides no direct right ventricular sup-
port. However, decompression of the left atrium
usually results in a decrease in pulmonary artery
pressure and right ventricular afterload.
Novacor® N100 LVAS. (The Edwards Life Sci-
ences Division, Worldheart Corp., Oakland,
CA). This device consists of a blood pump that is
implanted into the left upper quadrant, either with-
in the abdominal cavity or in a preperitoneal pock-
et. Inflow and outflow cannulae attach to the left
ventricular apex and the ascending aorta, respec-
tively. Bovine pericardial valves are located in the
cannulae and provide for unidirectional blood flow.
The pump comprises a seamless polyurethane sac
with two opposing pusher plates that are activated
by an electromagnetically driven solenoid. The me-
chanical failure rate of this system is extraordinari-
ly low, and is one of the strong points of the device.
An electric driveline/vent exits the body through a
stab wound in the abdominal wall. The driveline
connects to a small controller that connects to an
external console. The device operates in one of
three modes and, unlike the HeartMate, can be syn-
chronized to the patient’s electrocardiogram, allow-
ing for filling of the device during cardiac systole. It
can also be configured to operate in asynchronous
mode, which maximizes output during exercise by
adjusting the pump rate to device inflow (venous re-
turn). A maximum output of 10 L/min can be ob-
tained in this mode. A third mode of operation is
fixed rate. The portable controller with external
battery pack allows for several hours of untethered
mobility. Many of these patients can be discharged
to home with relatively normal mobility. The
longest duration of support thus far is greater than
3 years. To date, 1136 Novacor devices have been
implanted worldwide.
The Novacor LVAS requires systemic anticoagula-
tion. Like the HeartMate, it requires a BSA of at least
1.5 m2 and does not provide right ventricular support. 
CardioWest C-70® TAH (CardioWest Tech-
nologies, Inc., Tucson, AZ). This totally artificial
heart, the descendant of the Jarvik-7, is still in use in
several centers in the U.S. and Europe. The pneu-
matically driven prosthetic ventricles are made of
polyurethane. A four-layer polyurethane diaphragm
separates the air and blood sides of each artificial
ventricle. Two Medtronic-Hall valves (per ventricle)
provide for unidirectional blood flow. The native
ventricles are completely excised. The device is con-
nected to the native atria by Dacron cuffs and to the
great vessels by Dacron vascular prosthetic grafts via
a quick-connect system consisting of coated, rigid
polycarbonate segments. Pneumatic drivelines exit
the body through two incisions in the anterior ab-
dominal wall. The external console allows for ad-
justment of driveline pressure, systolic duration,
and pump rate, providing a maximal output of 9
L/min. The console is bulky, but a smaller drive unit
is under development. Stroke volume (70 cc with
maximum fill) is preload- dependent, allowing for
augmented device output during exercise.
The CardioWest TAH requires aggressive sys-
temic anticoagulation with a combination of war-
farin and antiplatelet agents. Implantation of this
device is limited to patients with a BSA of 1.7 m2. To
date, 155 CardioWest devices have been implanted
worldwide. In a world dominated, at present, by
pure left ventricular assist devices, there are some
scenarios (e.g., a primary intracardiac tumor) in
which a TAH is the treatment of choice.
Special Considerations, 
Complications, and Monitoring
Drivelines and External Cannula Sites. All of
the implantable devices listed above have drivelines
designed to promote tissue ingrowth. The Thoratec
and ABIOMED BVS 5000® transcutaneous blood
cannulae also share this design. Dacron velour is
the most commonly utilized material. The advan-
tage of this type of design (in comparison with the
skin buttons used in the original Jarvik-7 devices)
include a reduced incidence of ascending driveline
infections and better stability.
Right Heart Dysfunction. Right heart failure is a
common cause of morbidity and mortality in this
group of patients, particularly in those receiving uni-
ventricular left-sided assist devices. Failure of the right
side to deliver blood across the pulmonary vascular
bed can lead to low flow in a LVAD, with the potential
for device thrombosis. Factors influencing postopera-
tive right heart function include preoperative right
heart function, severity of right coronary artery (RCA)
distribution coronary disease (particularly in the ex-
treme case of RV infarction), modulation of pul-
monary vascular resistance by intraoperative blood
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products and cytokines related to cardiopulmonary
bypass, and myocardial preservation techniques em-
ployed during CPB. In general, the best defense is a
good offense. If profound or irreversible right-sided
dysfunction is anticipated, use of a TAH or BiVAD is
indicated over use of a LVAD. If a LVAD is implanted
(with the hope of eventual right-sided recovery), tran-
sient right-sided support using ECLS, an Abiomed
RVAD, or Thoratec RVAD may be required. Practical-
ly speaking, many patients can eventually be weaned
from right-sided support. It is estimated that
10%–20%22 of patients receiving LVADs will need at
least transient right ventricular support (RVAD, ECLS,
or nitric oxide).
Other measures that can be utilized to maximize
right-sided function include judicious preload aug-
mentation with fluids, minimization of pulmonary
vascular resistance (see below), tricuspid repair if se-
vere tricuspid regurgitation is present, use of in-
otropes, such as isoproterenol, milrinone, and
dobutamine, and pacing for chronotropic insufficien-
cy. Given the predilection for postoperative bleeding
in this group of patients, a high index of suspicion for
intrathoracic bleeding with focal right atrial or ven-
tricular tamponade is warranted. In case of poor de-
vice fit or transient chest wall edema, delayed sternal
closure may prevent right ventricular compression. 
In some patients with LVADs, profound right
heart dysfunction is not necessarily problematic. In
the setting of low pulmonary vascular resistance
and a minimally regurgitant tricuspid valve, the
ability to develop Fontan-like physiology (passive
flow across the pulmonary vascular bed) can allow
for adequate right to left flow with only minimal to
modest elevation in central venous pressure.
Pulmonary Hypertension. Although pulmonary
artery pressures frequently decrease after complete
unloading of the left chambers, some patients de-
velop reactive pulmonary hypertension in the intra-
operative or immediate postoperative period. This
is frequently in addition to some degree of mild to
moderate fixed pulmonary hypertension related to
chronic heart failure or intrinsic lung disease. The
pathophysiologic state of pulmonary hypertension
can have a profound impact on right ventricular
function, and ultimately left-sided filling and car-
diac/device output. 
Modulation of pulmonary vascular resistance fre-
quently can be achieved with pharmacologic or ven-
tilatory agents. Adequate pO2 and maintenance of
mild respiratory alkalosis are of fundamental impor-
tance. Inotropes, such as dobutamine, milrinone,
and isoproterenol, act as pulmonary vasodilators.
Intravenous nitrates and nitroprusside are useful as
long as systemic pressure is not compromised. In
extreme cases, intraoperative placement of a left
atrial line may allow for administration of systemic
circulation vasoconstrictor agents with concomitant
use of vasodilators on the venous/pulmonary side.
Administration of inhaled nitric oxide into the
ventilator circuit at a concentration of 20–40 ppm
can be particularly useful in the setting of right
heart failure associated with increased pulmonary
vascular resistance.23,24 The local action of this agent
allows for maximal pulmonary vasodilatation with
virtually no effects on systemic pressures. It is also
particularly helpful in managing post-transplant
right-sided failure. Our experience with this inert
gas has been positive, and results are sometimes
quite impressive (as well as immediate). The FDA
recently approved nitric oxide for the indication of
neonatal acute respiratory distress syndrome. Use in
adults is now off-label. Unfortunately, with market
approval, the cost to obtain this agent has become
prohibitively high for many institutions. 
In patients without LVADs, nitric oxide is not
safe to use in the setting of significantly elevated
left ventricular end-diastolic pressure. If pulmonary
vascular resistance is precipitously decreased in this
setting, left ventricular and pulmonary venous pres-
sures can acutely rise secondary to the increase in
right-to-left flow. This can result in severe pul-
monary edema.25 It is, therefore, imperative that
left ventricular filling pressure be normalized prior
to initiation of nitric oxide in this setting. However,
in the absence of mitral stenosis, a LVAD will effect
nearly complete pulmonary venous unloading,
making nitric oxide safe in this setting.
Arrhythmias. Ventricular decompression through
use of a ventricular assist device can decrease my-
ocardial ischemia and alleviate ventricular arrhyth-
mias. Decreased atrial stretch can also reduce the
frequency of atrial arrhythmias. Nonetheless, these
patients are still at high risk for arrhythmias. Seri-
ous arrhythmias, such as ventricular tachycardia or
fibrillation, can lead to hemodynamic instability in
some patients. In other patients, malignant ventricu-
lar arrhythmias will have virtually no effect if
Fontan-like right-to-left flow is adequate.26 Right
ventricular function and degree of pulmonary hy-
pertension play a large role in the hemodynamic re-
sponse of a patient to arrhythmia, particularly
ventricular arrhythmia. Therefore, arrhythmias are
less well tolerated in the first several days after de-
vice implantation because pulmonary vascular resis-
tance is frequently elevated and right ventricular
dysfunction is common in the immediate post-by-
pass physiologic state. Whether or not treatment for
an arrhythmia is indicated depends less upon the
type of ventricular assist device than on the patient’s
response to the arrhythmia. In the presence of an
isolated LVAD, atrial fibrillation with loss of atri-
oventricular mechanical coupling is usually well tol-
erated. If serious arrhythmias are likely to have
profound consequences in a patient who is to be
supported with a LVAD, a better choice would be
support with a BiVAD or TAH. 
Treatment with antiarrhythmic agents during
ventricular assist support is relatively common-
place. Since many of these patients are able to toler-
ate severe ventricular arrhythmias, some physicians
are more willing to use antiarrhythmic agents that
are potentially proarrhythmic (class IA and IC
agents). Amiodarone (a class III agent) is frequently
used. Although it is one of the safest and most effec-
tive antiarrhythmics in this group of patients, it
should be used judiciously. The very long half-life
of the drug can cause severe chronotropic insuffi-
ciency in the donor heart sinus node following the
transplant, for which implantation of a permanent
pacemaker may be required. 
Direct current cardioversion or defibrillation can
be performed in the presence of most ventricular
assist devices, but should not be performed (unless
absolutely necessary) without full knowledge of the
consequences to the electrical systems of the specif-
ic device being used. Temporary deactivation of the
device is desirable in order to prevent damage to
the electrical circuits. For this reason, internal car-
dioverter-defibrillators are frequently explanted at
the time of LVAD implantation. 
Given the side effect profile of most antiarrhyth-
mic agents, the occasional patient will be better off
with a sustained arrhythmia than with antiarrhyth-
mic therapy. Most patients with ventricular assist
devices are systemically anticoagulated, so the risk
of arrhythmia-associated embolic events is general-
ly low. The exception to this rule is the HeartMate
device, since systemic anticoagulation is not re-
quired. In the presence of significant arrhythmias,
heparin and/or warfarin should be added to the
regimen of HeartMate patients.
Perioperative Hemodynamic Monitoring. As a
consequence of the left ventricular (and therefore
left atrial) unloading afforded by LVADs, monitor-
ing of left atrial pressure is not clinically helpful,
even in the immediate postoperative period. Device
flow (a minimal estimate of actual forward cardiac
output) is provided on all of the device consoles.
Pulmonary artery catheters are therefore seldom
needed. Because at least some degree of postopera-
tive right heart dysfunction is present in many of
these patients, measurement of central venous pres-
sure is helpful in order to maintain adequate right-
sided filling pressures. Radial arterial lines are
essential for the first day or two. In the optimal situ-
ation, indwelling catheters can be removed within
24–48 hours, which aids in preventing secondary
device infections. 
Invasive hemodynamic monitoring with a pul-
monary artery catheter can be very helpful in some
situations in which device malfunction is suspected.
At our institution, we recently witnessed two cases
of LVAD inflow valve incompetence. A significant
regurgitant volume of blood between the device and
the left ventricle caused both device consoles to dis-
play a device output that was inappropriately high.
Measurement of the true cardiac output by the ther-
modilution technique, and of the actual pulmonary
capillary occlusive pressure in the setting of the se-
vere device regurgitation, allowed us to comfortably
decide against exchanging the devices. 
Infectious Complications. Due to the nature of
this group of patients and the procedures required to
sustain them, it is not surprising that infections are
commonplace. Although many of these are routine
infections, they are of particular concern because of
the endovascular nature of the implanted device and
the potential for seeding. Broad-spectrum antibiotic
use is routine, particularly in the peri-implantation
period. Because of this, many of the infections tend
to involve resistant organisms (for example, methi-
cillin-resistant staphylococcal species, vancomycin-
resistant enterococci, and fungal species). 
Rates of infection differ from center to center,
and have been quoted to be from 23%–58%,27–29
with most large series reporting around 50%. A rel-
atively high rate of fungal infections, usually candi-
dal species, has been noted. It is unclear if any
particular type of device is more prone to infectious
complications.
Many of the infectious complications can be
treated with local debridement, appropriate wound
care, and intravenous and/or oral antibiotics. An ex-
ample of this would be a local driveline infection,
which is fairly common. Even though minor, if not
managed appropriately, driveline infections can as-
cend and become a major device pocket infection
or mediastinitis. Major device-related infections can
require explantation and exchange for a new de-
vice, particularly if persistent bacteremia is present.
Many patients have been transplanted in the pres-
ence of a LVAD infection. In fact, at some centers,
urgent transplantation, using marginal donors if
necessary, is the treatment of choice for device in-
fections. Outcomes in perhaps the largest series
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have been relatively favorable, with a survival rate
to transplantation of 59%, as compared to 58% for
patients without LVAD infections.30 In this series,
infections after transplantation were also not signif-
icantly different (35% vs. 28%). In rare cases, the
best option is to explant the device and support the
patient with medical therapy until the infection
clears. In any case, infections will remain a problem
at least until trancutaneous energy transfer or inter-
nal battery systems replace traditional drivelines.
Given the fact that these devices are endovascular,
care should be taken to ensure appropriate antibiotic
prophylaxis during dental, airway, gastrointestinal,
and urogenital procedures. At the present time no
data exist concerning what type of antibiotic cover-
age should be used. At a minimum, AHA guidelines
for bacterial endocarditis (SBE) prophylaxis31 for
high risk patients (i.e., those with mechanical valves)
should be followed.
Panel Reactive Antibodies. For patients awaiting
transplant, panel reactive antibody (PRA) assays are
used to identify those who have been presensitized
to HLA antigens. A presensitized state is usually as-
sociated with prior organ transplant, blood product
transfusion, or multiparity. It has been shown that
patients with PRA levels of greater than 10% are
more likely to have difficulties with early rejec-
tion.32 At many centers, it is typical to require a
negative prospective lymphocytotoxic crossmatch
prior to heart transplantation in the setting of a
PRA of greater than 10%. The process of prospec-
tive crossmatching is time-consuming (which can
jeopardize organ viability), and the wait time for a
crossmatch-negative organ is typically significantly
longer than if no crossmatch is required.
These issues are particularly pertinent to patients
with ventricular assist devices, as there is a well
known association between the presence of an assist
device and elevated PRA levels. Why this occurs is
not completely understood, but the association is
likely to be a result of multiple factors. The use of
blood products (particularly platelets) during im-
plantation of these devices, the immunologic re-
sponse of the patient to the biomaterials within the
devices, and the length of exposure are all implicat-
ed. The development of a positive PRA after im-
plantation of an assist device appears to be
somewhat device-specific. Good data are sparse, but
the literature suggests that short-term devices, such
as the ABIOMED BVS 5000®, do not appear to stim-
ulate this immunologic reaction. The long-term de-
vices are more problematic.
The HeartMate devices appear to entail a higher
incidence of elevated PRA levels than the other de-
vices. In one series of 40 HeartMate patients, PRA
levels were found to be elevated in 45% of pa-
tients.33 The rate appeared to drop with the addi-
tion of leukocyte filters used to decrease the
perioperative antigenic load. In another series of
HeartMate patients, avoidance of cellular blood
products did not eliminate this problem.34 It is like-
ly that the textured surface design of the HeartMate
devices either modulates the immune system direct-
ly or plays some role in modulating the immuno-
logic response to foreign human leukocyte antigen
loads. Other devices, such as the CardioWest and
Novacor, appear to carry intermediate risk,35 al-
though only limited studies have been performed to
examine this issue as it relates to these devices. 
Clinical strategies for dealing with this problem in-
clude use of leukocyte filters for cellular blood prod-
ucts before, during, and after LVAD implantation,
with avoidance of blood products if possible, and the
use of drugs (aspirin or pentoxifylline) that may
down-regulate the immune response to antigenic
stimuli (by preventing activation of nuclear factor
kappaB in particular). If an elevated PRA is noted,
treatment options include the use of intravenous im-
munoglobulin, plasmapheresis, cytotoxic drugs, and
mycophenolate mofetil. We have avoided the last
three options because of the heightened risk of infec-
tion in the presence of an assist device. Once a signifi-
cant positive PRA level is noted, it is likely that the
waiting time for an organ (and device support time)
will be significantly longer because of the need for a
negative crossmatch. At our institution, we have noted
that patients who develop a positive PRA after Heart-
Mate implantation do not appear to have a higher in-
cidence of rejection as compared to controls and that
2-year survival does not appear to be affected.36 For
patients who are presensitized prior to placement of
an assist device, use of a less immunogenically active
device may, however, be considered. 
Thromboembolic Events. Thromboembolic (TE)
rates have long been a weakness of mechanical cir-
culatory devices. Rates of greater than 30% were
commonly reported in the late 1980s.37,38 However,
design changes and improved anticoagulation regi-
mens appear to have significantly reduced the risk,
and continual improvements make it difficult to
quote exact TE rates for each device. Rates for most
nontextured devices vary from 8%–35%.39,40 More
recent reviews support TE rates of 14% for the
ABIOMED BVS 5000® device (personal communi-
cation, Doug McNair), and 8% for the Thoratec de-
vice,40 with fewer TEs noted with ventricular
cannulation than with atrial cannulation. TE rates
for the Novacor device range from 10%–35%,39,41
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although with recent cannula modifications this rate
has been reduced to 5%42–12%.43 The addition of
antiplatelet agents may also contribute to the lower
rates observed recently.
TE events plagued the early years (and earlier
incarnations) of the CardioWest device. More re-
cent data demonstrate TE rates that range from
0%44–26%.45,46 The recent improvements in TE
rates with this device are probably related to more
sophisticated anticoagulation regimens, which in-
clude warfarin, dypyridamole, pentoxifylline, as-
pirin, ticlopidine, and clopidogrel. 
The HeartMate devices, with their textured sur-
face technology, appear to consistently have lower
TE rates. Most reports quote rates of 2%–4%.20,21
Survival Rates. In a recent report47 on the world-
wide experience with the HeartMate devices, sur-
vival rates (to transplant or explant) were noted to
be 71% for the IP-1000 LVAS and 58% for the VE
LVAS, with rates of 73% and 63%, respectively, in
the U.S.47 Survival rates at the Cleveland Clinic
have been as high as 76%.13 In our experience of 50
HeartMate implants, we have noted 80% survival to
transplantation, with 97% survival to discharge
after transplantation. In the Vented Electric bridge-
to-transplant trial, the 1-year post-transplant sur-
vival was 84% (personal communication, Laura
Damme).
Over one half of deaths during LVAD support
with any of the assist devices occur within the first
month of implantation. The HeartMate Registry
data illustrate this well (similar data exist for the
other LVADS). When these perioperative deaths are
excluded, worldwide survival is 87% for the IP-1000
LVAS and 79% for the VE LVAS, with rates of 88%
and 84%, respectively, in the U.S.47 This highlights
the importance of proper preoperative screening
and the possible use of ECLS as a bridge to LVAD
in selected high risk patients. 
In a review of international experience with the
CardioWest device, a survival to transplantation
rate of 69%, and post-transplant survival to dis-
charge rate of 92% were reported.48 In a smaller se-
ries of U.S. recipients of this device, a survival rate
of 93% was noted, with a post-transplant discharge
to home rate of 96%.46 In this series, survival to dis-
charge for the control group of patients (no device)
was only 39%. 
In a recent review of the worldwide experience
of the Novacor device, 58% of patients survived to
transplant and 89% of these patients survived to
discharge.42 In this review, 768 patients were im-
planted between 1984 and 1997. More recent data
from a registry of 22 U.S. centers (129 patients)
demonstrate a survival to transplantation rate of
76%.49 The University of Pittsburgh experience was
a survival to transplant rate of 72%, with 84% of
these patients surviving to discharge.42
Worldwide results for the Thoratec VAD System
(57% BiVAD, 40% LVAD, 3% RVAD) demonstrate a
survival to transplant rate of 60%, with 86% of these
patients surviving to discharge.50 Overall post-trans-
plant survival rates are comparable to the Interna-
tional Society for Heart and Lung Transplantation
(ISHLT) Registry data. No relationship has been
found between duration of VAD support and sur-
vival after transplantation.
From 1984 through 1996, a total of 1286 devices
(Thoratec, Novacor, HeartMate, and CardioWest)
were implanted worldwide as bridges to transplan-
tation. Overall survival to transplant during that era
was 60%, with 88.5% of those surviving to dis-
charge. After transplantation, survival to discharge
was similar for all devices, with rates between 81%
and 92%.51
Survival rates vary greatly from study to study, and
from center to center (even when the same device is
compared). Device improvements, increased clinical
expertise, better patient selection, and improved pre-
ventive strategies render data about survival rates
quickly out of date and survival comparisons between
devices limited. 
Which Device Should I Use? Given the rela-
tively small numbers of patients who require long-
term mechanical support, the rapidly evolving
technologies, and the large financial barriers, it is
unlikely that a randomized trial of existing devices
will ever be done. Also, it is likely that few, if any,
cardiac surgery centers will be able to support the
use of more than two or three types of devices. All
present forms of mechanical assist devices have in-
dividual strengths and weaknesses, some of which
are described above. None of the devices is clearly
superior to the rest, and each fills a particular
niche. Given these facts, the question of which de-
vices to use can be best answered by the type of
patient most likely to be seen at a given institu-
tion, the capabilities of that institution, and the
comfort level of all involved medical staff with
each device. 
As a rule, it is necessary to have several different
types of systems available. Each institution involved
in long-term support of patients should have a de-
vice that will provide short-term support, such as
ECLS, CP, or an ABIOMED BVS 5000®. For long-
term support, a Novacor N100, a TCI Heartmate, a
Thoratec, or a CardioWest should be available. In
addition, there should also be a mechanism for
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dealing with right ventricular failure. Options in-
clude nitric oxide (although on occasion this will
not be adequate), and ECLS, CP, ABIOMED BVS
5000, Thoratec or CardioWest devices. Centers not
committed to long-term support should have short-
term support available, particularly if an active car-
diology/cardiac surgery program is present.
Future of Ventricular Assist 
Devices and Artificial Hearts
It should be noted that the present use of ventricu-
lar assist systems does nothing to address the prob-
lem of a limited donor pool. In fact, it may actually
make the problem worse. Many patients who re-
ceive mechanical ventricular support would not
have survived to transplantation a few years ago.
The number of donor hearts available per year lev-
eled off several years ago, and in fact there has
been a disturbing trend toward a decrease in the
number of donors (United Network for Organ
Sharing [UNOS] registry data presented at the In-
ternational Society for Heart and Lung Transplan-
tation annual meeting, April, 2000). Mechanical
cardiac assist devices will likely provide at least a
partial solution to this problem.
In the very near future, there is likely to be an
increase in number of types of devices available to
us. This is largely due to rapid improvement in the
technology required for the design and testing of
new devices. In addition, the existing technology
will be applied to larger patient populations, and
for broader indications.
A good example of the broader use of existing
technology is the concept of implanting LVADs to
bridge to recovery. Certain subsets of patients may
benefit from long-term unloading of the left ventri-
cle with ultimate device explant. Improvement in
myocyte morphology,52 myocyte contractile proper-
ties, ß adrenergic responsiveness,53 the neurohor-
monal and cytokine profile,54 and left ventricular
contractility52 routinely have been demonstrated. It
is possible that significant myocyte recovery might
be achieved in some patients, to the extent that a
transplant is no longer necessary. 
A recent report from the German Heart Institute
in Berlin55 demonstrated successful device explan-
tation after a recovery period in five of 17 patients
with idiopathic dilated cardiomyopathy. Thus far,
these results have not been reproduced at other in-
tuitions.56 Reproducible prognostic indicators and
physiologic markers for patients who are potential
candidates for explantation have yet to be identi-
fied. Further discussion on this exciting topic is be-
yond the scope of this article.
Another good example of broader use of an exist-
ing technology is the Randomized Evaluation of Me-
chanical Assistance in the Treatment of Congestive
Heart Failure (REMATCH) trial.10 In this ongoing
trial, patients with end stage congestive heart failure
who are not transplant candidates (because of age or
other factors) are randomly assigned to either best
medical therapy or permanent (destination) implan-
tation of a HeartMate VE-LVAS. If this trial demon-
strates that quantity and quality of life are
significantly improved at an acceptable cost, then
LVAD implantation will become a viable option for
tens of thousands of patients in this country alone.
The Worldheart Corporation (formerly known as the
Novacor Division, Baxter Health Care Co.) has re-
cently received FDA approval for a feasability study,
the Investigation for Nontransplant Eligible Patients
Who are Inotrope Dependant (INTrEPID), which in-
volves the use of their device as a destination therapy
in comparison to standart medical therapy (personal
communication, Frank Beering).
As another example, Thoratec Laboratories is in
the process of developing an implantable ventricular
assist device, or IVAD.50 The design of the pump is
basically the same as that of the company’s existing
blood pump, with the advantage of having only one
exiting drive line as opposed to two exiting blood
cannulae. It will be significantly smaller than the
Novacor or HeartMate devices, and therefore will
benefit smaller patients. 
As for new technology, the trend in the near fu-
ture is for transcutaneous energy transfer systems
that will eliminate the need for drivelines. The first
human implant of the LionHeart™ occurred on Oc-
tober 26, 1999 in Germany. The LionHeart LVAS,
developed by Arrow International in collaboration
with Pennsylvania State University, utilizes a tran-
scutaneous energy transfer system, implanted bat-
teries, controller, and electrically powered blood
pump equipped with two tilting-disk valves. The de-
vice is entirely implantable. A compliance chamber,
placed in the left pleural space, allows for device
venting. A subcutaneous access port allows for peri-
odic percutaneous needle gas equilibration in order
to maintain gas volume within the system. Energy is
transferred via an external skin coil that is placed
over the internal coil, and internal batteries allow
for 20 minutes of untethered activity. The external
battery pack allows for 2–3 hours of power for mo-
bile operation away from the floor-based power
charger. Because of the presence of mechanical
valves, patients will require long-term systemic anti-
coagulation. This device has been designed as desti-
nation therapy, and not for bridge to transplant or
recovery, and is intended for class IV patients who
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are considered ineligible for heart transplantation.
A clinical trial of this device in a total of 30 patients
is ongoing in Europe. It is expected that the FDA
will approve this device for clinical trials in the U.S.
in the next few months. 
Thoratec Laboratories is currently developing a
muscle-powered ventricular assist device, or MVAD,50
designed to be used as an alternative to transplanta-
tion. The device converts the mechanical energy of a
stimulated latissimus dorsi into hydraulic energy that
drives the VAD. It is designed to be completely inter-
nal and free of external drivelines.
ABIOMED, Inc. is in the process of developing a
new TAH called the AbioCorTM.57 This device will
incorporate two artificial ventricles, polyurethane
valves, a motor-driven hydraulic pumping system, a
transcutaneous energy transmission system, and an
externally worn battery pack. It is being designed as
an alternative to transplant. Clinical trials of this
device, as well as the Penn State TAH (which will
also utilize a transcutaneous energy transmission
system) will likely begin within the next year or two.
Another technological advance that will be in
clinical use very soon is the axial flow pump. Several
groups are in the process of developing this type of
device. The NASA/DeBakey VADTM system, consists
of a titanium inflow cannula that connects the pump
to the apex of the left ventricle, a miniaturized axial
flow pump, and a vascular graft outflow cannula that
connects the pump to the ascending aorta. The de-
vice has a rotor speed of 10,000 rpm and can deliver
5 L/min. A driveline connects the device to an exter-
nal controller system. This device is the first axial
flow device used in humans.58 Thus far it has been
tested in approximately two dozen patients as a
bridge to transplantation. At present, this device is
under investigation in Europe.
The Jarvik-200059 device is a compact axial flow
impeller blood pump that is inserted into the left
ventricle through a sewing cuff anchored into the
left ventricular apex. A Dacron outflow graft is
anastomosed into the descending thoracic aorta.
The device is 2.5 x 5.5 cm, weighs 85 g, and has a
displacement volume of 25 ml (a pediatric version
of the same pump is even smaller). It operates at
speeds of 8000–12,000 rpm and can provide non-
pulsatile blood flow of 8 L/min. There are no
valves. Although it is designed as a LVAD, it is
possible that it can be configured to function as a
RVAD or BiVAD. A distinct advantage of this de-
vice is that it is quiet, unlike existing devices. The
present incarnation of this device has a small driv-
eline cable; however, a transcutaneous energy sys-
tem will likely be available in the near future.
Animal studies with this device have been promis-
ing. The first implantation of the Jarvik-2000 in a
human occurred several weeks prior to the com-
pletion of this article.
Thermo Cardiosystems is currently developing a
similar axial flow impeller device, the Nimbus/TCI
device, also called the HeartMate II.20 Clinical tri-
als using this device in humans are scheduled to
begin in the summer of 2000 in Israel. The Sun
Medical/HIJ/Waseda/Pittsburgh axial flow pump is
also under development. These new devices will
broaden our patient population to include smaller
adults as well as children. 
Conclusion
As we enter the new millennium, our options for
treating patients with end stage heart failure, surgi-
cal as well as medical, will continue to expand.
Hundreds of thousands of patients will benefit from
the future generations of devices that arise from our
present-day cardiac assist technology.
REFERENCES
1 Dale HH, Schuster EHJ. A double perfusion pump. J Physiol.
1928;64:356–364.
2 DeBakey ME. A simple continuous flow blood transfusion in-
strument. New Orleans Med Surg J. 1934;87:386–389.
3 DeVries WC, Joyce LD. The artificial heart. Clin Symposia.
35(6):1–32.
4 Gibbon JH Jr. Application of a mechanical heart and lung
apparatus to cardiac surgery. Minn Med. 1954;37:171–180. 
5 Akutsu T, Kolff WJ. Permanent substitutes for valves and
hearts. Trans Am Soc Artif Intern Organs. 1958;4:230–235.
6 Kantrowitz A, Tjonneland S, Freed PS, et al. Initial clinical
experience with intraaortic balloon pumping in cardiogenic
shock. JAMA. 1968;203(2):113–118.
7 Cooley DA, Liotta D, Hallman GL, et al. Orthotopic cardiac
prosthesis for two-staged cardiac replacement. Am J Cardiol.
1969;24(5):723–730.
8 DeVries WC, Anderson JL, Joyce LD, et al. Clinical use of the
total artificial heart. N Engl J Med. 1984;310(5):273–278.
9 Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular
assist devices. N Engl J Med. 1998;339(21):1522–1533.
10 Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH
trial: Rationale, design, and end points. Randomized Evalua-
tion of Mechanical Assistance for the Treatment of Conges-
tive Heart Failure. Ann Thorac Surg. 1999;67(3):723–730.
11 Reinhartz O, Farrar DJ, Hershon JH, et al. Importance 
of preoperative liver function as a predictor of survival in 
patients supported with Thoratec ventricular assist devices 
as a bridge to transplantation. J Thorac Cardiovasc Surg.
1998;116(4):633–640.
12 Pagani FD, Lynch W, Swaniker F, et al. Extracorporeal life
support to left ventricular assist device bridge to heart trans-
plant: A strategy to optimize survival and resource utilization.
Circulation. 1999;100(suppl 19):II206–210. 
13 McCarthy PM, Smedira NO, Vargo RL, et al. One hundred
patients with the HeartMate left ventricular assist device:
Evolving concepts and technology. J Thorac Cardiovasc Surg.
1998;115(4):904–912.
14 Frazier OH, Macris MP, Myers TJ, et al. Improved survival
after extended bridge to cardiac transplantation. Ann Thorac
Surg. 1994;57(6):1416–1422. 
15 Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts
patients successfully receiving long-term implantable left ven-
tricular assist devices. Circulation. 1995;92(suppl 9):II169–73.
CHF  SEPTEMBER/OCTOBER 2000270 CIRCULATORY ASSIST DEVICES 2000
16 Mehta SM, Aufiero TX, Pae WE Jr, et al. Mechanical ventricu-
lar assistance: An economical and effective means of treating
end-stage heart disease. Ann Thorac Surg. 1995;60(2):284–290. 
17 Morales DL, Catanese KA, Helman DN, et al. Six-year expe-
rience of caring for forty-four patients with a left ventricular
assist device at home: Safe, economical, necessary. J Thorac
Cardiovasc Surg. 2000;119(2):251–259.
18 Gelijns AC, Richards AF, Williams DL, et al. Evolving costs 
of long-term left ventricular assist device implantation.
Ann Thorac Surg. 1997;64(5):1312–1319.
19 Moscucci M, Lynch W, Swaniker F, et al. Atrial balloon sep-
tostomy in the management and prevention of pulmonary he-
morrhage in patients requiring extracorporeal life support.
Extracorporeal Life Support Organization 9th annual meet-
ing, Ann Arbor, MI; 1999.
20 Poirier VL. Worldwide experience with the TCI HeartMate
system: Issues and future perspective. Thorac Cardiovasc Surg.
1999;47(suppl 2):316–320.
21 Rose EA, Levin HR, Oz MC, et al. Artificial circulatory sup-
port with textured interior surfaces: A counterintuitive ap-
proach to minimizing thromboembolism. Circulation.
1994;90(5 pt II):II87–91. 
22 Arabia FA, Smith RG, Rose DS, et al. Success rates of long-
term circulatory assist devices used currently for bridge to
heart transplantation. ASAIO J. 1996;42(5):M542–546.
23 Argenziano M, Choudhri AF, Moazami N, et al. Randomized,
double-blind trial of inhaled nitric oxide in LVAD recipients
with pulmonary hypertension. Ann Thorac Surg. 1998;
65(2):340–345.
24 Hare JM, Shernan SK, Body SC, et al. Influence of inhaled
nitric oxide on systemic flow and ventricular filling pressure
in patients receiving mechanical circulatory assistance (pub-
lished erratum. Circulation. 1997;96(3):1065). Circulation.
1997;95(9):2250–2253.
25 Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of
inhaled nitric oxide in patients with left ventricular dysfunc-
tion. Circulation. 1994;90(6):2780–2785.
26 Oz MC, Rose EA, Slater J, et al. Malignant ventricular 
arrhythmias are well tolerated in patients receiving 
long-term left ventricular assist devices. J Am Coll Cardiol.
1994;24(7):1688–1691.
27 Myers TJ, McGee MG, Zeluff BJ, et al. Frequency and signifi-
cance of infections in patients receiving prolonged LVAD
support. ASAIO Trans. 1991;37:M283–285. 
28 Frazier OH, Duncan JM, Radovancevic B, et al. Successful
bridge to heart transplantation with a new left ventricular as-
sist device. J Heart Lung Transplant. 1992;11:530–537. 
29 Kormos RL, Murali S, Dew A, et al. Chronic mechanical cir-
culatory support: Rehabilitation, low morbidity, and superior
survival. Ann Thorac Surg. 1994;57:51–58. 
30 Argenziano M, Catanese KA, Moazami N, et al. The influ-
ence of infection on survival and successful transplantation in
patients with left ventricular assist devices. J Heart Lung
Transplant. 1997;16(8):822–831.
31 Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacter-
ial endocarditis. Recommendations by the American Heart
Association. Circulation. 1997;96(1):358–366.
32 Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panel-
reactive antibody and lymphocytotoxic crossmatch on sur-
vival after heart transplantation. J Heart Lung Transplant.
1991;10(6):921–929.
33 Moazami N, Itescu S, Williams MR, et al. Platelet transfusions
are associated with the development of anti-major histocompat-
ibility complex class I antibodies in patients with left ventricular
assist support. J Heart Lung Transplant. 1998;17(9):876–880.
34 Stringham JC, Bull DA, Fuller TC, et al. Avoidance of cellu-
lar blood product transfusions in LVAD recipients does not
prevent HLA allosensitization. J Heart Lung Transplant.
1999;18(2):160–165.
35 Tsau PH, Arabia FA, Toporoff B, et al. Positive panel reactive
antibody titers in patients bridged to transplantation with a
mechanical assist device: Risk factors and treatment. ASAIO J.
1998;44(5):M634–637.
36 Pagani FD, Dyke DB, Wright S, et al. Development of anti-
major histocompatibility complex class I or II antibodies follow-
ing LVAD implant: Effects on subsequent allograft rejection
and survival (abstract). J Heart Lung Transplant. 2000;19(1):57.
37 Icenogle TB, Smith RG, Cleavinger M, et al. Thromboembol-
ic complications of the Symbion AVAD System. Artificial Or-
gans. 1989;13(6):532–538.
38 Levinson MM, Smith RG, Cork RC, et al. Thromboembolic
complications of the Jarvik-7 total artificial heart: Case re-
port. Artificial Organs. 1986;10(3):236–244.
39 Wagner WR, Johnson PC, Kormos RL, et al. Evaluation of
bioprosthetic valve-associated thrombus in ventricular assist
device patients. Circulation. 1993;88(5 pt 1):2023–2029.
40 Farrar DJ, Hill JD. Univentricular and biventricular Thoratec
VAD support as a bridge to transplantation. Ann Thorac Surg.
1993;55(1):276–282.
41 Kormos RL, Murali S, Dew MA, et al. Chronic mechanical
circulatory support: Rehabilitation, low morbidity, and supe-
rior survival. Ann Thorac Surg. 1994;57(1):51–57.
42 Murali S. Mechanical circulatory support with the Novacor
LVAS: World-wide clinical results. Thorac Cardiovasc Surg.
1999;47(suppl 2):321–325.
43 Ramasamy N, Wheeldon D, Jansen P, et al. Reduction of em-
bolic complications in left ventricular assist systems (LVAS)
recipients: Impact of inflow conduit design (abstract). J Heart
Lung Transplant. 2000;19(1):58.
44 Szefner J. Control and treatment of hemostasis in cardiovas-
cular surgery. The experience of La Pitie Hospital with 
patients on total artificial heart. Int J Artificial Organs.
1995;18(10):633–648.
45 Johnson KE, Prieto M, Joyce LD, et al. Summary of the clini-
cal use of the Symbion total artificial heart: A registry report.
J Heart Lung Transplant. 1992;11(1pt1):103–116.
46 Copeland JG III, Arabia FA, Banchy ME, et al. The Cardio-
West total artificial heart bridge to transplantation: 1993 to
1996 national trial. Ann Thorac Surg. 1998;66(5):1662–1669.
47 HeartMate LVAS Clinical Results, January 2000. Data on file
with Thermo Cardiosystems Inc. 
48 Copeland JG, Arabia FA, Smith RG, et al. Arizona experience
with CardioWest total artificial heart bridge to transplanta-
tion. Ann Thorac Surg. 1999;68(2):756–760.
49 Kormos RL, Ramasamy N, Sit S, et al, for the U.S. Multi-
center Investigators. Bridge-to-transplant (BTT) experi-
ence with the Novacor Left Ventricular Assist System
(LVAS): Results of a multicenter study. J Heart Lung 
Transplant. 1999;18(1):63. 
50 Thoratec VAD System Clinical Monograph. January, 2000.
51 Arabia FA, Smith RG, Rose DS, et al. Success rates of long-
term circulatory assist devices used currently for bridge to
transplantation. ASAIO J. 1996;42(5):M542–546.
52 Frazier OH, Benedict CR, Radovancevic B, et al. Improved
left ventricular function after chronic left ventricular unload-
ing. Ann Thorac Surg. 1996;62(3):675–681.
53 Dipla K, Mattiello JA, Jeevanandam V, et al. Myocyte recov-
ery after mechanical circulatory support in humans with end-
stage heart failure. Circulation. 1998;97(23):2316–2322.
54 Delgado R III, Radovancevic B, Massin EK, et al. Neurohor-
monal changes after implantation of a left ventricular assist
system. ASAIO J. 1998;44(4):299–302.
55 Muller J, Wallukat G, Weng YG, et al. Weaning from me-
chanical cardiac support in patients with idiopathic dilated
cardiomyopathy. Circulation. 1997;96(2):542–549.
56 Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence
of myocardial recovery after left ventricular assist device im-
plantation in patients with chronic heart failure. Circulation.
1998;98(22):2383–2389.
57 Abiomed Annual Report, 1998. Danvers, MA.
58 Wieselthaler GM, Schima H, Hiesmayr M, et al. First clinical
experience with the DeBakey VAD continuous-axial-flow pump
for bridge to transplantation. Circulation. 2000;101(4):356–359.
59 Westaby S, Katsumata T, Houel R, et al. Jarvik 2000 heart:
Potential for bridge to myocyte recovery. Circulation.
1998;98(15):1568–1574.
CHF  SEPTEMBER/OCTOBER 2000CIRCULATORY ASSIST DEVICES 2000 271
